Novo Nordisk to continue largest insulin brand Mixtard supply in vials amid penfill device phase-out

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation of widely used insulin products. The company aims to consolidate its insulin portfolio to meet increasing patient demand and ensure a stable medicine supply, focusing on newer treatments.